Objective COVID-19 vaccines have shown efficacy and safety in healthy people. However, cancer patients under active immunosuppressive treatment were not included in the clinical trials conducted to test vaccines' efficacy and safety. This study aimed to evaluate the COVID-19 vaccine acceptance in cancer patients undergoing immunosuppressive therapy. Methods A total of 200 adult cancer patients received a questionnaire between March 8 and April 2, 2021, before the beginning of cancer patients' vaccination in Portugal. The questionnaire adapted from previously conducted studies included 11 close-ended items, evaluating variables such as patient sociodemographic and clinical characteristics, and the acceptance and underlying reasons to be or not to be vaccinated. The primary outcome was the intended acceptance of the COVID-19 vaccine in cancer patients. Multiple logistic regression was performed to identify factors associated with intended acceptance. Results Among the 200 delivered questionnaires, only 169 were included in this study. From those, 142 (84%) patients intended to be vaccinated against COVID-19. Only 27 participants (16%) had not yet decided or were reluctant to COVID-19 vaccination. High school degree (odds ratio (OR) 0.133, 95% confidence interval (C.I.) 0.031-0.579, p = 0.007], rural residence (OR 0.282, 95% C.I. 0.081-0.984, p = 0.047), and reluctance in believing in the vaccine efficacy (OR 0.058, 95% C.I. 0.016-0.204, p < 0.001] were identified predictors factor for COVID-19 vaccine hesitancy. Conclusion Most patients intended to be vaccinated against COVID-19, and specific factors such as education level, rural residence and the belief in vaccine efficacy were related to vaccine acceptance.

No abstract

Background: Cancer p represent a high-risk population for severe COVID-19. Cancerassociated immunosuppression may hinder in the development of anti-SARS-CoV-2 antibodies.

Conclusions:The majority of prostate cancer patients reported at least mild anxiety and mild depression. In this analysis of real-world evidence, cancer stage, PSA at diagnosis, treatments, and side-effects, were among the factors affecting patients in several ways. The multiple determinants of emotional wellbeing of prostate cancer patients warrant more research and offer the opportunity for personalised interventions.

IntroductionCancer patients on active treatment are at increased risk of developing coronavirus disease 2019 , making effective immunization of the utmost importance. However, the effectiveness of vaccination in this population is still unclear. This study aims to evaluate the response against COVID-19 in a cohort of patients with active cancer under immunosuppressive therapy. MethodsThis was a prospective, cross-sectional, single-center study that included patients with cancer under immunosuppressive therapy vaccinated against COVID-19 between April and September 2021. Exclusion criteria were: previous known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, single-dose vaccine or incomplete vaccination scheme. Immunoglobulin G (IgG) anti-SARS-CoV-2 antibody levels were assessed using 35.2 binding antibody units (BAU)/mL as the positive cut-off. Assessments were performed 14-31 days after the first and second dose and three months after the second dose. ResultsA total of 103 patients were included. The median age was 60 years. Most patients were being treated for gastrointestinal cancer (n=38, 36.9%), breast cancer (n=33, 32%) or head and neck cancer (n=18, 17.5%). At evaluation, 72 patients (69.9%) were being treated with palliative intent. The majority were being treated with chemotherapy (CT) alone (57.3%). At the first assessment, levels of circulating SARS-CoV-2 IgG consistent with seroconversion were present in 49 patients (47.6%). At the time of the second assessment, 91% (n=100) achieved seroconversion. Three months after the second dose, 83% (n=70) maintained levels of circulating SARS-CoV-2 IgG consistent with seroconversion. In this study, no SARS-CoV-2 infection was reported in the study population. ConclusionsOur findings suggest that this group of patients had a satisfactory COVID-19 immunization response. Although promising, this study should be replicated on a wider scale in order to validate these findings.

O cancro do colo do útero (CCU) é globalmente um dos tipos de cancro mais comum em mulheres. O rastreio do CCU é indispensável para a deteção e tratamento de lesões neoplásicas cervicais que possam evoluir para neoplasia, com o objectivo de reduzir a incidência deste cancro. Nos últimos anos, têm ocorrido alterações que visam o aumento da eficácia do rastreio. Nomeadamente, o uso de teste de deteção do vírus do papiloma humano como método de rastreio primário do CCU e a valorização da importância de adaptar a prática clínica em função do risco de desenvolvimento do CCU. Desta forma, são necessárias novas normas de atuação clínica, que contemplem esta mudança de paradigma. Assim, um grupo de especialistas analisou e discutiu a literatura mais recente, definindo recomendações e propondo normas de prática clínica que se focam na estratificação de risco, avaliação diagnóstica, e na conduta terapêutica e de seguimento de mulheres com resultados dos testes de rastreio alterados. Este trabalho tem como objetivo facilitar a prática clínica em resposta a resultados alterados nos testes e, consequentemente, melhorar a prevenção secundária do CCU.

No abstract

RESUMONos últimos anos, um número crescente de mulheres adia o seu projeto reprodutivo para idades mais avançadas, sendo por isso cada vez mais importante que se avalie a possibilidade e a segurança de tratamentos conservadores que preservem a fertilidade em pacientes jovens com carcinoma do endométrio. O tratamento recomendado para o carcinoma do endométrio é a histerectomia total com salpingo-ooforectomia, o que interfere, como é óbvio, na fertilidade da mulher, não sendo por isso recomendável em mulheres que pretendem preservar a sua função reprodutora. Em alternativa, o tratamento conservador pode ser uma opção de exceção em casos bem selecionados. Contudo, a decisão de efetuar tratamento conservador não está isenta de riscos, nomeadamente os riscos de estadiar e/ou tratar inadequadamente o carcinoma do endométrio e os riscos de não diagnosticar tumores ováricos síncronos ou metastáticos. Além disso, não há consenso quanto ao tratamento ideal por quanto tempo deve ser prolongado, como efetuar a vigilância destas doentes e qual o resultado oncológico a longo prazo. O caso presente, no conhecimento dos autores, é o primeiro documentado em Portugal de gravidez após tratamento conservador de carcinoma do endométrio, numa mulher jovem. PALAVRAS-CHAVE: Neoplasias do Endométrio; Preservação da Fertilidade